first booster dose - versus complete primary vaccine series - for COVID-19 prophylaxis (excluding children) pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 0.09 [0.04, 0.19]< 155%3 studies (-/3)100.0 %moderatenot evaluable moderatecrucial-
hospitalization or death 0.34 [0.15, 0.77]< 159%2 studies (-/2)99.5 %NAnot evaluable crucial-
confirmed COVID (any severity) 0.23 [0.16, 0.32]< 199%11 studies (1/10)100.0 %NAlow important-
hospitalization 0.11 [0.06, 0.21]< 192%7 studies (-/7)100.0 %NAnot evaluable important-
symptomatic Covid-19 0.37 [0.24, 0.56]< 195%3 studies (-/3)100.0 %NAnot evaluable important-
ICU admission 0.33 [0.08, 1.36]< 10%1 study (-/1)93.7 %NAnot evaluable non important-
severe COVID-19 (FDA definition) 0.25 [0.01, 5.50]< 10%1 study (1/-)80.8 %NAnot evaluable non important-
severe COVID-19 occurrence 0.06 [0.05, 0.08]< 10%4 studies (1/3)100.0 %NAnot evaluable non important-

safety endpoints 00

arrhythmia 1.99 [0.07, 59.22]< 10%1 study (1/-)34.8 %NAnot evaluable non important-
hypertension 0.50 [0.02, 14.80]< 10%1 study (1/-)65.5 %NAnot evaluable non important-
Myocardial infarction 0.74 [0.17, 3.33]< 10%1 study (1/-)65.0 %NAnot evaluable non important-
pulmonary embolism 0.17 [0.01, 3.30]< 10%1 study (1/-)87.8 %NAnot evaluable non important-
stroke (non-specific, hemorrhagic, and ischemic) 0.99 [0.06, 15.88]< 10%1 study (1/-)50.2 %NAnot evaluable non important-

AE of interest endpoints 00

cerebral venous sinus thrombosis (CVST) 0.50 [0.02, 14.80]< 10%1 study (1/-)65.5 %NAnot evaluable important-
appendicitis 3.97 [0.18, 88.14]< 10%1 study (1/-)19.4 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.